World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2024
Volume: 3; Issue: 4
Page: 212-224

A REVIEW ON THE THERAPEUTIC POTENTIAL OF GENE THERAPY IN NEUROLOGICAL DISORDERS

Dr. Swapna Moparthi[1]*, S. Priyadharshini[2], Dr. Sowjanya Kondru[3], Dr. Srinivasarao Varagani[4], Dhruvi Pandit[5], Mohammed Abdul Qader[6], Morziul Haque[7], Shaikh Mohammed Taher[8], Kohale Dhiraj Arvind[9], Gopalkumar Sunilkumar Singh[10]

[1]Masters in Healthcare Informatics. swapnamoparthi@gmail.com
[2]Pharm.D, Swamy Vivekanandha College of Pharmacy, Elayampalayam, Tiruchengode, Namakkal. dharshinipharmd2020@gmail.com
[3]Pharm.D, Chalapathi Institute of Pharmaceutical Sciences, Guntur. sowjanyakkm@gmail.com
[4]Pharm.D, Duty Medical Officer, Viswabharathi Super Speciality Hospital, Guntur. varaganisrinivasarao1998@gmail.com
[5]Pharm.D, Anand Pharmacy College, Anand, Gujarat. dhruvi18pandit25@gmail.com
[6]Pharm D, Shadan college of Pharmacy, Peerancheru, Telangana. qaderbadul245@gmail.com
[7]Doctor of Pharmacy, University Institute of Pharma Sciences, Chandigarh University. haquemorziul69@gmail.com
[8]Pharm D, Shadan College of Pharmacy, Perancheru, Telangana, Hyderabad. shaikhtaher162@gmail.com
[9]Doctor of Pharmacy (Pharrn.D), Government College of Pharmacy, Chh Sambhaji Nagar, Maharashtra. kohaledhiraj9@gmail.com
[10]Pharm D, Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat. dr.gopalsuryavanshi@gmail.com

Article Received: 21 June 2024 | | ***Article Revised: 12 July 2024*** | | ***Article Accepted: 02 August 2024***

***Corresponding Author: Dr. Swapna Moparthi**
Masters in Healthcare Informatics.
DOI: https://doi.org/10.5281/zenodo.13320814

How to cite this Article: Dr. Swapna Moparthi*, S. Priyadharshini, Dr. Sowjanya Kondru, Dr. Srinivasarao Varagani, Dhruvi Pandit, Mohammed Abdul Qader, Morziul Haque, Shaikh Mohammed Taher, Kohale Dhiraj Arvind, & Gopalkumar Sunilkumar Singh. (2024). A REVIEW ON THE THERAPEUTIC POTENTIAL OF GENE THERAPY IN NEUROLOGICAL DISORDERS. World Journal of Pharmaceutical Science and Research, 3(4), 212–224. https://doi.org/10.5281/zenodo.13320814

ABSTRACT

Gene therapy is a novel way to treating neurological illnesses, potentially curing some of the most difficult and incurable conditions at this time. This review examines the therapeutic potential of gene therapy for a range of neurological illnesses, with an emphasis on the mechanisms underlying these effects, such as cell-based therapies, gene silencing, gene editing, gene insertion, and gene control. Gene therapy offers intriguing pathways to address the underlying causes of neurological illnesses by repairing genetic defects, lowering toxic protein levels, improving neuroprotection, restoring gene function, and offering long-term solutions. The review focuses on important developments in tailored treatment plans, gene delivery techniques, and ongoing research initiatives that are influencing the direction of gene therapy. A thorough discussion of the therapeutic effects of gene therapy is provided, with an emphasis on how it may change treatment paradigms and enhance patient outcomes for diseases like spinal muscular atrophy, Huntington's disease, ALS, Parkinson's disease, and other neurological disorders.

KEYWORDS: Gene Therapy, Neurological Disorders, Gene Addition, Gene Silencing, Gene Editing, CRISPR-Cas9, TALENs, ZFNs, Gene Regulation, Personalized Medicine, Neuroprotection, Cell-Based Therapies.

INTRODUTION

There is a wide spectrum of illnesses that impact the brain, spinal cord, and nerves that are classified as neurological disorders. These conditions can have a substantial negative effect on a person's quality of life and cause symptoms that can be minor to severe. There is increasing interest in more cutting-edge therapy techniques because traditional therapies for neurological illnesses sometimes concentrate on controlling symptoms rather than treating the underlying causes. Gene therapy is one such exciting strategy that may provide more potent and long-lasting treatments for a range of neurological disorders.

Numerous illnesses, including Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), Huntington's, multiple sclerosis (MS), and several types of epilepsy, are classified as neurological disorders. These illnesses may result from infections, environmental variables, genetic alterations, or unidentified causes. They are typified by increasing neuronal malfunction or degeneration, which impairs motor, cognitive, and sensory abilities. The intricacy and variety of neurological conditions present formidable obstacles to the identification, management, and advancement of science.[1,2,3]

Importance and Challenges in Treating Neurological Disorders

Because neurological illnesses have such a profound effect on people and society, treating them is essential. Patients, families, and healthcare systems may bear a significant financial cost as a result of these disorders, which can cause severe disability, loss of independence, and shortened life expectancy. Among the difficulties in treating neurological conditions are:

1. **Complex Pathophysiology**: It is challenging to comprehend the underlying causes of neurological illnesses due to the intricate nature of the brain and nervous system. The development of effective medicines is hampered by this intricacy.
2. **Lack of Disease-Modifying Therapies**: A lot of the medications available today merely manage symptoms; they don't change how the disease progresses. The need for treatments that can slow the course of a disease and provide long-term advantages is urgent.
3. **Genetic and Environmental Factors**: Determining exact therapy targets is made more difficult by the interaction between environmental triggers and genetic predispositions. Implementing personalized medicine approaches is difficult yet vital.
4. **Blood-Brain Barrier**: Although the BBB shields the brain from dangerous drugs, it also limits the flow of therapeutic substances into the brain. Getting beyond this obstacle is a major step toward creating therapies that work.
5. **Clinical Trial Design**: Because many neurological disorders proceed slowly, patient populations vary, and it can be difficult to measure results that are relevant, conducting clinical studies in this area can be difficult.

   Novel treatments that can target the underlying causes of neurological illnesses are desperately needed in light of these difficulties. One intriguing approach to creating such therapies is gene therapy, which entails adding, removing, or changing genetic information within a patient's cells.[4,5,6]

GENE THERAPY

Gene therapy is a cutting-edge method of treating illnesses by altering or modifying the genetic material contained in a patient's cells. This cutting-edge method promises more potent and long-lasting treatments by replacing or repairing

damaged genes that cause a variety of hereditary illnesses. Gene therapy shows great potential in the setting of neurological illnesses, where a large number of conditions are caused by genetic mutations or abnormalities in neural function. Gene therapy may open the door to revolutionary advancements in treatment approaches by targeting the underlying molecular causes of many ailments, giving patients with conditions that are now difficult to manage fresh hope.[7,8]

Historical Background

There have been a number of significant advancements in gene therapy, particularly in the area of neurological disorders:

1. **Early Foundations (1950s-1970s)**: Watson and Crick's 1953 discovery of the DNA double helix structure gave rise to the basic knowledge of genetic information transfer and storage. Advances in molecular biology and this discovery paved the way for more studies on gene therapy.
2. **Initial Gene Transfer Experiments (1980s)**: Gene therapy made tremendous strides in the first part of the 1980s. Scientists started experimenting with gene-transfer techniques. The viability of this strategy was proven in 1980 when the first successful gene transfer into a human cell using a retroviral vector was accomplished.
3. **First Clinical Trials (1990s)**: In 1990, the National Institutes of Health (NIH) in the United States conducted the first clinical trial using gene therapy on a small girl who had severe combined immunodeficiency (SCID). This trial marked a turning point in clinical research by demonstrating the possibility of gene therapy to cure hereditary diseases.
4. **Early Challenges and Setbacks (2000s)**: The industry encountered many difficulties, such as ethical and safety-related ones. Notably, a patient died in a gene therapy experiment for a rare metabolic condition, underscoring the need for stronger safety protocols and regulatory supervision. These failures led to a reassessment of approaches and a heightened focus on managing possible hazards.
5. **Technological Advancements (2010s-Present)**: The development of CRISPR-Cas9 and other gene-editing technologies signaled a paradigm shift in gene therapy. With the help of these instruments, the genome might be precisely edited, improving the accuracy of genetic flaw correction. The effectiveness and safety of gene therapy techniques have been substantially improved by developments in viral vectors and non-viral delivery methods. Furthermore, customized therapies based on unique genetic profiles are now possible because to the advancement of personalized medicine methodologies.[9,10]

TYPES OF GENE THERAPY

In Vivo Gene Therapy: Delivering therapeutic genes straight into the patient's body is known as "in vivo gene therapy." This technique transfers genetic material to specific cells or tissues inside the patient using vectors, which are frequently modified viruses. The principal benefit of in vivo gene therapy is in its capacity to treat illnesses without necessitating intricate procedures or external body interventions for the patient. Nonetheless, obstacles include of guaranteeing that the vector targets the targeted cells exclusively and doesn't trigger an immune reaction. Viral infections, some types of cancer, and genetic diseases are among the illnesses for which this approach is commonly used.

Ex Vivo Gene Therapy: The process of genetically altering a patient's cells outside of their body and then reintroducing them into the patient is known as ex vivo gene therapy. This method usually entails taking patient cells—

such as bone marrow or blood cells—and employing vectors to introduce the therapeutic genes into those cells. The cells are successfully modified, grown in a lab, and then reinfused into the patient. Ex vivo gene therapy is frequently used to treat diseases like some forms of cancer and genetic disorders like severe combined immunodeficiency (SCID). It provides a more regulated environment to boost the efficacy of gene transport and expression. The main benefit of this approach is that the cells may be meticulously observed and manipulated prior to reintroduction; nevertheless, the cell collection and processing process necessitates a more invasive technique.[11,12,13]

DELIVERY METHODS IN GENE THERAPY

Effective delivery strategies are essential for delivering genetic material into target cells in gene therapy.

Viral Vectors: Viral vectors are modified viruses that are used to introduce therapeutic genes into target cells. They are useful instruments for gene therapy because of their innate capacity to integrate genetic material into cells and cause infection. Many varieties of viral vectors are frequently used, such as:

- **Adenoviral Vectors:** These vectors have a high transduction efficiency and can infect a variety of cell types since they use adenoviruses to transfer genes. However, their long-term expression is limited because they do not integrate into the host DNA.
- **Lentiviral Vectors:** These vectors, which are derived from lentiviruses, have the ability to incorporate therapeutic genes into the genome of the host cell, enabling stable and sustained gene expression. They are very helpful in treating genetic abnormalities and in gene therapies that target stem cells.
- **Adeno-Associated Viral (AAV) Vectors:** AAV vectors are well-known for their low immunogenicity and capacity to infect both dividing and non-dividing cells. They provide long-term expression by integrating into a particular location on the host DNA. Nevertheless, in comparison to other viral vectors, their cargo capacity is restricted.
- **Retroviral Vectors:** These vectors provide long-term gene expression by integrating therapeutic genes into the host genome through the use of retroviruses. They are frequently employed in hematopoietic stem cell-focused gene treatments.[14,15,16]

Non-Viral Vectors: Non-viral vectors are substitutes for viral vectors that transfer therapeutic genes into cells by physical or chemical means. They may be less effective in delivering genes, but they are often easier to make and have a lower chance of triggering an immunological reaction. Typical non-viral vectors consist of:

- **Liposomes:** Liposomes are nanoparticles based on lipids that contain therapeutic genes that combine with cell membranes to introduce genetic material into cells. It is possible to create liposomes to decrease toxicity and increase delivery efficiency.
- **Polymeric Nanoparticles:** These carriers encapsulate and safeguard therapeutic genes using biodegradable polymers. They have the capacity for targeted delivery and can be made to discharge their cargo in a controlled manner.
- **Electroporation:** With this method, cells are exposed to an electrical field, which causes transient holes in the cell membrane that permit the uptake of therapeutic genes. It is frequently employed in clinical settings as well as research.

- **Gene Guns:** This technique delivers genes across cell membranes by using high-velocity, DNA-coated gold or tungsten particles. It is mostly applied to plant and animal tissues for research purposes as well as in certain medicinal applications.

The choice of vector is frequently based on the particular criteria of the gene therapy application, such as the illness type, target cells, and desired duration of gene expression. Each type of vector has advantages and disadvantages of its own.[17,18,19]

MECHANISMS OF GENE THERAPY IN NEUROLOGICAL DISORDERS

Gene Addition

Gene addition is the process of replacing a missing or malfunctioning gene in a patient's cells with a new or therapeutic gene. This method seeks to provide the genes required for the production of proteins vital to normal brain function in neurological diseases. For example, gene addition therapy can provide a functioning copy of the SMN1 gene, which is essential for motor neuron survival in disorders such as spinal muscular atrophy (SMA). Once incorporated into the patient's cells, this new gene gets translated into a functional protein, which may reduce symptoms and delay the course of the illness. Gene addition techniques frequently make use of viral vectors, including adeno-associated viruses (AAV), which are designed to effectively transfer the therapeutic gene into the target cells.

Gene Silencing

In order to mitigate a gene's negative effects, gene silence entails lowering or stopping the expression of that particular gene. This method works especially well for diseases where dangerous genes are overexpressed. For instance, gene silencing strategies are used to try and prevent the production of the mutant HTT gene, which causes the poisonous huntingtin protein, in neurological illnesses like Huntington's disease. A popular technique for gene silencing is called RNA interference (RNAi), which works by degrading the target mRNA and stopping translation with the help of small interfering RNA (siRNA) or short hairpin RNA (shRNA). Gene silencing therapy can lower harmful protein levels and possibly slow the progression of the disease by specifically silencing the troublesome gene.[20,21]

Gene Editing (CRISPR-Cas9, TALENs, ZFNs)

The genome can be precisely modified thanks to gene editing technologies like CRISPR-Cas9, TALENs (Transcription Activator-Like Effector Nucleases), and ZFNs (Zinc Finger Nucleases). Gene editing has the ability to directly fix genetic mutations at the cause of neurological diseases. For example, CRISPR-Cas9 directs the Cas9 nuclease to a particular DNA sequence where it causes a double-strand break using a guide RNA. The mutation is subsequently fixed by the cell's own repair mechanisms, which might also introduce a new, right sequence. ZFNs and TALENs have comparable functions, but they modify the genome in different ways by utilizing different DNA-binding domains. These methods provide a path toward possibly curative medicines by correcting genes that cause diseases like Duchenne muscular dystrophy or specific types of inherited epilepsy.

Gene Regulation

The goal of gene regulation is to alter the expression levels of particular genes in order to change the course of a disease or restore normal function. This method uses chemicals or regulatory elements to affect gene activity rather than changing the genetic code itself. Gene regulation can be used to either increase or decrease the expression of genes implicated in neurological diseases. For instance, it is possible to create regulatory elements such as enhancers or

repressors to regulate the activity of genes related to neurodegeneration or neuroprotection. One can use methods like optogenetics or tiny chemicals to precisely regulate gene expression in response to outside inputs. This dynamic regulation of gene expression presents a viable approach to the treatment of illnesses with intricate genetic foundations or erratic symptoms.[22,23,]

SPECIFIC NEUROLOGICAL DISORDERS AND GENE THERAPY APPLICATIONS

Many neurological illnesses, each with unique therapeutic potential and limitations, may benefit from gene therapy. The following are some instances of certain neurological conditions and the potential uses of gene therapy for them:

1. **Spinal Muscular Atrophy (SMA): Muscle atrophy and weakening result from the progressive degradation of motor neurons in sickle cell anemia (SMA). Delivering a functioning copy of the SMN1 gene, which is faulty in SMA patients, is the goal of gene therapy, which attempts to treat the underlying genetic issue. One well-known instance is the FDA-approved gene therapy Zolgensma (onasemnogene abeparvovec), which transfers a copy of the SMN1 gene using an adeno-associated virus (AAV) vector. Significant therapeutic benefits of this therapy have been shown, including increased motor function and survival rates in SMA newborns.

2. **Duchenne Muscular Dystrophy (DMD): Muscle degeneration and weakening result from Duchenne Muscular Dystrophy (DMD), a severe form of muscular dystrophy brought on by mutations in the dystrophin gene. The goal of DMD gene therapy techniques is to use viral vectors to convey a functional dystrophin gene or smaller, functional variants, like micro-dystrophins. AAV vectors are being used in an attempt to delay the progression of the disease and restore muscle function by introducing genes related to dystrophin.

3. **Parkinson's Disease: A neurodegenerative condition called Parkinson's disease is typified by the death of dopaminergic neurons in the brain. In order to treat Parkinson's disease, genes that can either repair or preserve these neurons are inserted. One tactic is to supply genes that encode neurotrophic factors, which enhance the survival and function of neurons. Examples of these factors are glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF). Using gene editing methods to fix mutations in genes like PINK1 or LRRK2, which are linked to family forms of Parkinson's disease, is an additional strategy.

4. **Huntington's Disease: The enlarged CAG repeat in the HTT gene, which results in the creation of a toxic protein that harms neurons, is the hereditary etiology of Huntington's disease. The goal of gene therapy techniques is to lessen or completely eradicate the mutant HTT gene's expression. Methods being investigated include targeting and degrading the mutant HTT gene's mRNA with RNA interference (RNAi) or antisense oligonucleotides (ASOs), which lowers the synthesis of the harmful protein.

5. **Amyotrophic Lateral Sclerosis (ALS): Amyotrophic Lateral Sclerosis (ALS) is a neurological illness that affects motor neurons and causes atrophy and weakening in the muscles. Targeting particular genetic variants linked to family forms of the illness, such as those in the SOD1 or C9orf72 genes, is one of the ALS gene therapy approaches. Methods include correcting or silencing the mutant genes using ASOs or gene editing methods like CRISPR/Cas9.

6. **Rett Syndrome: Mutations in the MECP2 gene cause Rett syndrome, a neurodevelopmental condition that primarily affects females. Delivering a functioning copy of the MECP2 gene or utilizing gene editing to fix mutations

in the MECP2 gene are two approaches to gene therapy for Rett syndrome. These methods seek to lessen the neurological symptoms connected to Rett syndrome while restoring normal gene function.[24,25,26]

THERAPEUTIC POTENTIAL OF GENE THERAPY IN NEUROLOGICAL DISORDERS

Gene therapy has enormous and dramatic therapeutic potential for neurological illnesses, providing new hope for conditions for which there are now few available treatments. The following outlines its possible advantages for a number of neurological disorders:

1. Restoring Gene Function

Genes that are lacking or malfunctioning in neurological illnesses can be made functional again by gene therapy. Therapies have the ability to fix underlying genetic abnormalities by providing functional copies of genes. For instance, the goal of gene addition therapy for spinal muscular atrophy (SMA) is to supply a functional copy of the SMN1 gene, which is essential for the survival of motor neurons. Patients' general quality of life and motor function may significantly improve as a result.

2. Correcting Genetic Mutations

Cutting-edge gene editing tools like CRISPR-Cas9 provide the opportunity to directly fix genetic mutations at the source. Due to this accuracy, mutations causing a number of neurological conditions, including Duchenne muscular dystrophy and Huntington's disease, can be corrected. Gene editing has the potential to lessen or eliminate disease symptoms and offer a permanent treatment by specifically targeting and fixing mutations.

3. Reducing Toxic Protein Levels

The expression of genes that create toxic proteins, which are linked to a number of neurological illnesses, can be reduced by the use of gene silencing strategies. For example, in Amyotrophic Lateral Sclerosis (ALS), blocking the mutant SOD1 gene can lessen the build-up of harmful SOD1 protein, which may slow down the course of the disease and enhance patient outcomes.

4. Enhancing Neuroprotection

The expression of genes involved in neuroprotection and neurodegeneration can be modulated by employing gene regulatory techniques. Therapeutic interventions can give novel approaches to the management of diseases like Parkinson's disease by modulating the activation of genes that promote neuronal health or inhibit detrimental processes. For instance, promoting neurotrophic factor expression by means of gene regulation may help maintain the viability and functionality of neurons.

5. Providing Long-Term Solutions

By addressing the underlying cause of neurological problems, gene therapy may provide long-term or even permanent treatments. Gene therapy attempts to target the genetic foundation of the condition, perhaps leading to long-lasting improvements or a cure, in contrast to traditional treatments that may just control symptoms.

6. Personalized Medicine

Personalized treatment options are made possible by the versatility of gene therapy procedures. Gene therapy can offer individualized, more effective, and less likely to have negative side effects treatments by customizing them to a

patient's unique genetic composition and illness features. The probability that treatment outcomes will be successful is increased by this customized strategy.

7. Innovative Delivery Methods

The effectiveness and safety of gene therapy are improved by developments in gene delivery techniques, such as the use of viral vectors and cell-based therapies. Adeno-associated viruses (AAVs) are employed to transfer therapeutic genes to specific neurons, and stem cells with altered genes can offer continuous therapeutic advantages. These developments enhance the capacity to more efficiently access and treat impacted brain areas.

Gene therapy has enormous therapeutic potential for neurological disorders since it targets the underlying genetic causes of many illnesses, provides long-term remedies, and opens the door to individualized and cutting-edge medical interventions. The impact of gene therapy on neurological disorders is anticipated to increase as science and technology develop, giving patients fresh hope and revolutionizing the discipline of neurology.[27,28,29]

CHALLENGES AND LIMITATIONS OF GENE THERAPY IN NEUROLOGICAL DISORDERS

Scientists and medical professionals are attempting to overcome the many obstacles and restrictions associated with gene therapy for neurological illnesses. These are a few of the main concerns:

1. **Delivery to the Central Nervous System (CNS): Effectively delivering therapeutic genes to the central nervous system is a major hurdle. The blood-brain barrier (BBB) prevents the majority of chemicals from entering the brain, including gene treatments and viral vectors. Innovative delivery strategies are needed to get beyond this obstacle, such as intrathecal injections, convection-enhanced transport, or the use of specific vectors. However, each of these strategies has drawbacks and restrictions of its own.

2. **Vector Safety and Efficacy: Selecting the appropriate vector is essential to the accomplishment of gene therapy. Though efficient in delivering genes, viral vectors carry certain dangers including immunological responses, insertional mutagenesis (the process by which the vector merges into unwanted regions of the genome), and toxicity linked with the vector. Even if they are less immunogenic, non-viral vectors frequently have problems with gene expression levels and transport effectiveness.

3. **Long-Term Expression and Stability: In the brain, sustaining gene expression is difficult to achieve. Certain vectors, like AAV, can express a gene over an extended period of time; however, other vectors might not integrate into the genome or might break down with time. The long-term effectiveness of the treatment depends on the therapeutic gene being expressed at high enough quantities over prolonged periods of time.

4. **Immune Responses: The produced therapeutic protein or the transported vectors may be recognized by the immune system, which could result in unfavorable outcomes or decreased efficacy. Given that viral vectors have the potential to elicit powerful immunological reactions, this problem is very important. Effective gene therapy requires methods to reduce these reactions or create tolerogenic strategies.

5. **Targeting Specific Neuronal Populations: Particular neuronal subtypes or brain areas are frequently impacted by neurological illnesses. It is difficult to precisely target these neurons without harming other, healthy neurons. For gene therapy to be both safe and successful, methods to increase specificity and reduce off-target effects are essential.

6. **Genetic Heterogeneity: There is a broad spectrum of genetic mutations or variants associated with many neurological illnesses. This genetic variety makes it difficult to develop a gene treatment that works for everyone. Although developing customized methods or treatments for certain genetic alterations may be necessary, they can also be more difficult and expensive.

7. **Ethical and Regulatory Issues: Gene therapy presents ethical and regulatory issues, particularly when used to neurological illnesses. These include concerns about germline modification, informed consent, and the long-term effects of genetic therapies. It is imperative to navigate these ethical and regulatory environments in order to develop and use gene treatments responsibly.

8. **Cost and Accessibility: Gene treatments can be costly, especially for uncommon or complicated neurological conditions. One persistent problem in the industry is making sure that patients who require these medicines can get them, while simultaneously addressing issues with cost and reimbursement.

To tackle these obstacles, continued investigation, technological development, and rigorous evaluation of scientific and ethical aspects are necessary. If these fields continue to advance, gene therapy may one day be a practical and efficient treatment for a wider variety of neurological conditions.[30,31,32]

ADVANCES AND INNOVATIONS IN GENE THERAPY

Gene therapy's potential and applicability have been greatly increased by recent developments and breakthroughs. The following are a few noteworthy developments:

1. **CRISPR/Cas9 and Gene Editing Technologies: Because they allow for precise alterations to the genome, CRISPR/Cas9 and other gene editing tools like CRISPR/Cas12 and CRISPR/Cas13 have transformed gene therapy. These technologies enable the insertion of therapeutic genes, the silencing of genes, and the targeted correction of genetic mutations. Advancements in CRISPR technology, including enhanced delivery methods and diminished off-target consequences, are augmenting its suitability for a broader spectrum of genetic illnesses.

2. **Advances in Viral Vectors: In order to increase the safety and effectiveness of viral vectors, especially adeno-associated viruses (AAVs), significant work has been made in this area. There is ongoing development of novel AAV serotypes and modified vectors with improved tissue selectivity and decreased immunogenicity. Hybrid vectors and vectors with enhanced ability to transfer bigger therapeutic genes are examples of innovations.

3. **Non-Viral Delivery Methods: Moreover, non-viral gene delivery techniques are developing. The effectiveness and targeting of gene therapies are being enhanced by methods like nanoparticle-based delivery systems, which include lipid and polymeric nanoparticles. To improve gene transfer and expression, improvements are being made to electroporation and other physical techniques.

4. **Gene Therapy for Rare and Complex Diseases: The use of gene therapy is growing in the treatment of difficult and rare diseases for which there were no effective previous treatments. Innovations in gene therapies aimed at uncommon metabolic disorders like phenylketonuria (PKU) and medicines for hereditary retinal diseases like Leber's congenital amaurosis are two examples.

5. **In Vivo Gene Editing**: Advances in in vivo gene editing methods enable direct genome change inside the patient's body. Techniques like base editing and prime editing present the possibility of more accurate and effective genetic mutation repairs without breaking DNA strands twice.

6. **Combination Therapies: More successful treatments may result from combining gene therapy with other therapeutic modalities including gene-editing, small drugs, or immunotherapies. This strategy can address several facets of complex diseases and improve the effectiveness of gene treatments.

7. **Personalized Gene Therapy: More individualized methods of gene therapy are now possible thanks to developments in genomics and bioinformatics. Researchers can create more specialized and potent treatments by customizing therapies to each patient's unique genetic profile.

8. **Regenerative Medicine and Stem Cell-Based Therapies: Regenerative medicine, stem cell technologies, and gene therapy are opening the door to treatments that can replace or repair damaged tissues. For instance, hereditary diseases and specific cancers are being treated with stem cells that have had their genes altered.

9. **Ethical and Regulatory Innovations: Gene therapy is progressing thanks to ongoing developments in regulatory frameworks and ethical criteria. In order to assure the safe and equitable implementation of gene therapy, new rules and regulatory frameworks are being devised to handle its particular issues.

10. **Improved Patient Monitoring and Outcomes: The capacity to monitor the efficacy and safety of gene treatments is being improved by developments in outcome metrics and monitoring systems. In order to monitor treatment outcomes and control possible side effects, better diagnostic instruments and biomarkers are being developed. With new hope for treating a variety of hereditary and acquired illnesses, these advancements are propelling the field of gene therapy ahead. In the upcoming years, it is anticipated that continued research and development will broaden the application and influence of gene treatments.[33,34,35]

CONCLUSION

Treating neurological illnesses using gene therapy presents a novel approach to addressing the underlying genetic origins of these intricate conditions, putting it at the forefront of transformational treatments. Gene therapy provides the potential to not only manage symptoms but also cure some of the most difficult neurological illnesses through novel approaches such gene insertion, silencing, editing, and regulation, as well as improvements in cell-based therapies. The study highlights the substantial breakthroughs in individualized treatment plans and efficient gene delivery techniques, emphasizing how these developments lead to more effective and focused therapy.

Even with the encouraging promise, there are still a number of obstacles to overcome, such as the requirement for better delivery methods, extended safety and efficacy testing, and more widespread access to these innovative therapies. To overcome these obstacles and fulfill the full potential of gene therapy, ongoing research and clinical trials are crucial. Gene therapy is expected to become more and more important in the management and treatment of neurological illnesses as the field develops, providing patients with improved prospects and a higher standard of living.
To summarize, gene therapy represents a paradigm change in the treatment of neurological illnesses, with the potential to profoundly transform the landscape of neurology and patient outcomes. Continued innovation, rigorous research, and

collaborative efforts will be critical in turning these therapeutic potentials into practical, widely accessible treatments that can significantly improve the lives of those suffering from neurological illnesses.

REFERENCES

1. Borsook D. Neurological diseases and pain. Brain, 2012 Feb; 135(Pt 2): 320-44.
2. Garofalo M, Pandini C, Bordoni M, Pansarasa O, Rey F, Costa A, Minafra B, Diamanti L, Zucca S, Carelli S, Cereda C, Gagliardi S. Alzheimer's, Parkinson's Disease and Amyotrophic Lateral Sclerosis Gene Expression Patterns Divergence Reveals Different Grade of RNA Metabolism Involvement. Int J Mol Sci, 2020 Dec 14; 21(24): 9500.
3. Stephenson J, Nutma E, van der Valk P, Amor S. Inflammation in CNS neurodegenerative diseases. Immunology, 2018 Jun; 154(2): 204-219.
4. Ningrum DNA, Kung WM. Challenges and Perspectives of Neurological Disorders. Brain Sci, 2023 Apr 18; 13(4): 676.
5. Thakur K.T., Albanese E., Giannakopoulos P., Jette N., Linde M., Prince M.J., Steiner T.J., Dua T. Neurological Disorders. In: Patel V., Chisholm D., Dua T., Laxminarayan R., Medina-Mora M.E., editors. *Mental, Neurological, and Substance Use Disorders: Disease Control Priorities.* 3rd ed. Volume 4 The International Bank for Reconstruction and Development/The World Bank; Washington, DC, USA: 2016.
6. Feigin V.L., Vos T., Nichols E., Owolabi M.O., Carroll W.M., Dichgans M., Deuschl G., Parmar P., Brainin M., Murray C. The global burden of neurological disorders: Translating evidence into policy. *Lancet Neurol,* 2020; 19: 255–265. doi: 10.1016/S1474-4422(19)30411-9.
7. Choong CJ, Baba K, Mochizuki H. Gene therapy for neurological disorders. Expert Opin Biol Ther, 2016; 16(2): 143-59.
8. Pena SA, Iyengar R, Eshraghi RS, Bencie N, Mittal J, Aljohani A, Mittal R, Eshraghi AA. Gene therapy for neurological disorders: challenges and recent advancements. J Drug Target, 2020 Feb; 28(2): 111-128.
9. Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology, 2017; 120: 11–19.
10. Sadeghi MR. Technical Problems and Ethical Concerns Regarding Gene Editing in Human Germlines and Embryos. J Reprod Infertil, 2023 Jul-Sep; 24(3): 145-146.
11. Bulcha, J.T., Wang, Y., Ma, H. *et al.* Viral vector platforms within the gene therapy landscape. *Sig Transduct Target Ther*, 2021; 6: 53.
12. Gowing G, Svendsen S, Svendsen CN. Ex vivo gene therapy for the treatment of neurological disorders. Prog Brain Res, 2017; 230: 99-132.
13. Rosanwo TO, Bauer DE. Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy. Mol Ther, 2021 Nov 3; 29(11): 3163-3178.
14. Bulcha, J.T., Wang, Y., Ma, H. *et al.* Viral vector platforms within the gene therapy landscape. *Sig Transduct Target Ther*, 2021; 6: 53.
15. Ghosh S, Brown AM, Jenkins C, Campbell K. Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Appl Biosaf, 2020 Mar 1; 25(1): 7-18.
16. Poletti V, Mavilio F. Designing Lentiviral Vectors for Gene Therapy of Genetic Diseases. Viruses, 2021 Aug 2; 13(8): 1526.

17. Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res, 2015 Jan; 9(1): GE01-6.
18. Ponder KP. *In An introduction to molecular medicine and gene therapy. Edited by Kresnia TF*. Newyork, USA: John wiley & sons Inc; 2000. Vectors in gene therapy; pp. 77–112.
19. Chen CK, Huang PK, Law WC, Chu CH, Chen NT, Lo LW. Biodegradable Polymers for Gene-Delivery Applications. Int J Nanomedicine, 2020 Mar 30; 15: 2131-2150.
20. Parambi DGT, Alharbi KS, Kumar R, Harilal S, Batiha GE, Cruz-Martins N, Magdy O, Musa A, Panda DS, Mathew B. Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases. Mol Neurobiol, 2022 Jan; 59(1): 191-233.
21. El-Sappah AH, Yan K, Huang Q, Islam MM, Li Q, Wang Y, Khan MS, Zhao X, Mir RR, Li J, El-Tarabily KA, Abbas M. Comprehensive Mechanism of Gene Silencing and Its Role in Plant Growth and Development. Front Plant Sci, 2021 Sep 7; 12: 705249.
22. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol, 2013 Jul; 31(7): 397-405.
23. Statello, L., Guo, CJ., Chen, LL. *et al.* Gene regulation by long non-coding RNAs and its biological functions. *Nat Rev Mol Cell Biol*, 2021; 22: 96–118.
24. Christine C. W., Bankiewicz K. S., Van Laar A. D., Richardson R. M., Ravina B., Kells A. P., et al., Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease. *Ann. Neurol*, 2019; 85(5): 704–714. 10.1002/ana.25450.
25. Albert K., Voutilainen M. H., Domanskyi A., Airavaara M., AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models. *Genes (Basel)*, 2017; 8(2). 10.3390/genes8020063.
26. Gatto EM, Rojas NG, Persi G, Etcheverry JL, Cesarini ME, Perandones C. Huntington disease: Advances in the understanding of its mechanisms. Clin Park Relat Disord, 2020 May 6; 3: 100056.
27. Paul A, Collins MG, Lee HY. Gene Therapy: The Next-Generation Therapeutics and Their Delivery Approaches for Neurological Disorders. Front Genome Ed., 2022 Jun 22; 4: 899209.
28. Dos Santos Rodrigues B., Kanekiyo T., Singh J., ApoE-2 Brain-Targeted Gene Therapy through Transferrin and Penetratin Tagged Liposomal Nanoparticles. *Pharm. Res.*, 2019; 36(11): 161. 10.1007/s11095-019-2691-7.
29. Choong CJ, Baba K, Mochizuki H. Gene therapy for neurological disorders. Expert Opin Biol Ther, 2016; 16(2): 143-59.
30. Ghosh S, Brown AM, Jenkins C, Campbell K. Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges. Appl Biosaf, 2020 Mar 1; 25(1): 7-18.
31. Piguet F, de Saint Denis T, Audouard E, Beccaria K, André A, Wurtz G, Schatz R, Alves S, Sevin C, Zerah M, Cartier N. The Challenge of Gene Therapy for Neurological Diseases: Strategies and Tools to Achieve Efficient Delivery to the Central Nervous System. Hum Gene Ther, 2021 Apr; 32(7-8): 349-374.
32. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov, 2019 May; 18(5): 358-378.
33. You L, Tong R, Li M, Liu Y, Xue J, Lu Y. Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research. Mol Ther Methods Clin Dev, 2019 Mar 15; 13: 359-370.

34. Henderson ML, Zieba JK, Li X, Campbell DB, Williams MR, Vogt DL, Bupp CP, Edgerly YM, Rajasekaran S, Hartog NL, Prokop JW, Krueger JM. Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care. BioTech (Basel), 2024 Jan 3; 13(1): 1.
35. Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs. Mol Ther Methods Clin Dev, 2021 Apr 5; 21: 524-529.